KARLA OW: Open Payments
NPI 1841614492 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$992 in 12 payments from 8 companies in 2025. Trend: 2023 $319 · 2024 $546 · 2025 $992
Food & beverage: $914Education: $78
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 3 | $234 |
| Merck Sharp & Dohme LLC | 2 | $215 |
| Daiichi Sankyo Inc. | 1 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $122 |
| Gilead Sciences, Inc. | 1 | $112 |
| Immunocore Limited | 1 | $91 |
| Celgene Corporation | 2 | $48 |
| Legend Biotech USA Inc. | 1 | $28 |
Products named: KEYTRUDA, CARVYKTI, DATROWAY, LIBTAYO, Trodelvy, KIMMTRAK, DARZALEX, REBLOZYL.
Industry payments across TX — which companies pay providers there.
